Suchergebnisse - "Hong, Lingzhi"

PubPharm (43)

1

Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

enthalten in: Nature communications | 2024

von Sujit, S. | Aminu, M. | Karpinets, T. | +34

2

Synthetic PET from CT improves diagnosis and prognosis for lung cancer : Proof of concept

enthalten in: Cell reports. Medicine | 2024

von Salehjahromi, M. | Karpinets, T. | Sujit, S. | +34

3

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Wang, K. | Du, R. | Myall, N. | +24

4

Clinical Benefit from Docetaxel +/- Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy

enthalten in: Cancers | 2024

von Qin, K. | Wang, K. | Li, S. | +17

5

Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma

enthalten in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2023

von Chen, P. | Rojas, F. | Hu, X. | +25

6

ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Vokes, N. | Galan Cobo, A. | Fernandez-Chas, M. | +21

7

Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Thummalapalli, R. | Ricciuti, B. | Bandlamudi, C. | +25

8

Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis

enthalten in: Cancers | 2023

von Diao, S. | Chen, P. | Showkatian, E. | +18

9

Brief Report : Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC

enthalten in: JTO clinical and research reports | 2023

von Wang, K. | Du, R. | Roy-Chowdhuri, S. | +22

10

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning : a retrospective study

enthalten in: The Lancet. Digital health | 2023

von Saad, M. | Hong, L. | Aminu, M. | +46

CommentIn: Lancet Digit Health. 2023 Jul;5(7):e396-e397. - PMID 37268450

1
2
3
4
5
Nächster »
[5]